Alector Inc [ALEC] stock is trading at $6.20, up 3.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALEC shares have gain 5.26% over the last week, with a monthly amount drifted -2.67%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Alector to Participate in Upcoming Healthcare Conferences. In a post published today on Yahoo Finance, Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:.
From an analyst’s perspective:
Alector Inc [NASDAQ: ALEC] stock has seen the most recent analyst activity on December 14, 2023, when Stifel upgraded its rating to a Buy and also boosted its price target to $15 from $8. Previously, Deutsche Bank started tracking the stock with Buy rating on December 12, 2023, and set its price target to $12. On September 25, 2023, Goldman initiated with a Sell rating and assigned a price target of $4 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $13 on September 22, 2023. BofA Securities downgraded its rating to a Neutral and reduced its price target to $12 on January 06, 2023. Morgan Stanley downgraded its rating to Equal-Weight for this stock on September 09, 2022, and downed its price target to $13. In a note dated July 07, 2022, Mizuho initiated an Buy rating and provided a target price of $15 on this stock.
Alector Inc [ALEC] stock has fluctuated between $3.66 and $9.06 over the past year. Alector Inc [NASDAQ: ALEC] shares were valued at $6.20 at the most recent close of the market.
Analyzing the ALEC fundamentals
Alector Inc [NASDAQ:ALEC] reported sales of 97.06M for the trailing twelve months, which represents a growth of 5.19%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.29%, and Net Profit Margin reading is -1.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.77 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.98 points at the first support level, and at 5.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.36, and for the 2nd resistance point, it is at 6.52.
Alector Inc [ALEC] reported earnings per share of -$0.49 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.77/share, meaning a difference of $0.28 and a surprise factor of 36.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.53 per share as compared to estimates of -$0.66 per share, a difference of $0.13 representing a surprise of 19.70%.
Ratios To Look Out For
For context, Alector Inc’s Current Ratio is 3.18. As well, the Quick Ratio is 3.18, while the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 6.12, the price to book ratio is 3.92.
Transactions by insiders
Recent insider trading involved Rosenthal Arnon, Chief Executive Officer, that happened on Mar 04 ’24 when 18837.0 shares were sold. President and Head of R&D, Kenkare-Mitra Sara completed a deal on Mar 04 ’24 to sell 10169.0 shares. Meanwhile, Chief Medical Officer Romano Gary sold 6001.0 shares on Mar 04 ’24.
